D.E. Shaw & Co
SPRO icon

D.E. Shaw & Co’s Spero Therapeutics SPRO Stock Holding History

D.E. Shaw & Co’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-649,334
Closed -$481K – 5508
2022
Q2 		$481K Buy
649,334
+630,688
+3,382% +$1.83M ﹤0.01% 4111
2022
Q1 		$162K Buy
+18,646
New +$191K ﹤0.01% 4921

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

D.E. Shaw & Co's SPRO Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Spero Therapeutics (SPRO) in Q3 2022, closing a stake of 649,334 shares — an estimated $481K sold.

D.E. Shaw & Co first reported a position in SPRO in Q1 2022 and held it in 2 quarters. The position peaked at $481K in Q2 2022. 69 funds tracked by Wall St. Rank hold SPRO as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Spero Therapeutics position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 649,334 Spero Therapeutics shares in Q3 2022, an estimated $481K.
  • D.E. Shaw & Co first reported a position in Spero Therapeutics in Q1 2022 and held it in 2 quarters.
  • D.E. Shaw & Co's Spero Therapeutics position peaked at $481K in Q2 2022.
  • 69 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.